# TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

> **NCT07082803** · PHASE1 · RECRUITING · sponsor: **Treeline Biosciences, Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Lymphoma
- Lymphoma, Non Hodgkin

## Interventions

- **DRUG:** TLN-121
- **DRUG:** TLN-254
- **DRUG:** TLN-121

## Key facts

- **NCT ID:** NCT07082803
- **Lead sponsor:** Treeline Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-23
- **Primary completion:** 2030-09
- **Final completion:** 2030-11
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07082803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07082803, "TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07082803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*